RNS Number:4584E
Hikma Pharmaceuticals Plc
12 June 2006



                            Section 198 Notification

London, 12 June 2006 - On 12 June 2006, Hikma Pharmaceuticals PLC (LSE: HIK) 
(DIFX: HIK) ("the Company") received notification from The Capital Group 
Companies, Inc., pursuant to Section 198 Companies Act 1985, that at the close 
of its business on 31st May 2006, The Capital Group Companies, Inc., on behalf 
of its affiliates, including Capital Research and Management Company, had an 
interest in 6,183,441 ordinary shares of 10p each in the Company, which 
represents 3.696 per cent of the issued ordinary share capital of the Company, 
as follows:

                              No. of shares       Percent of ordinary 
                                                  shares outstanding
The Capital Group
Companies, Inc.       
held as follows:              6,183,441           3.696%

Capital Research and
Management Company            
of which:                     6,183,441           3.696%

SMALLCAP World Fund           5,029,591           3.007%

Registered holders:

State Street Nominees Limited                     5,029,591

Chase Nominees Limited                            1,153,850

                               Total              6,183,441

                                    - ENDS -

Enquiries:


Hikma Pharmaceuticals PLC                             +44 20 7399 2670
Henry Knowles, Company Secretary
Susan Ringdal, Investor Relations Director

Brunswick Group LLP                                   +44 20 7404 5959
Jon Coles / Justine McIlroy / Alex Tweed

Notes to Editors

About Hikma

Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ("MENA") region and Europe. In 2005, the Group
had revenue of $262 million and profit attributable to shareholders of $44
million. At 31 December 2005, the Group had over 1,800 employees. For news and
other information, please visit www.hikma.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
HOLILFVDRDIFLIR
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.